Clinical Trial Update: A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 study evaluating HB-2121 as a diagnostic for celiac disease has been completed. The study assessed safety and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Celiac Disease

Drugs mentioned

• HB-2121

Snippet

Sponsor: Nielsen Fernandez-Becker | Conditions: Celiac Disease, Healthy | Phase 1 | Status: COMPLETED